Publications

Dr. Pavel Klein

  1. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-1088.
  2. Herzog AG, Klein P, Jacobs AR. Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology 1998; 50:782-784.
  3. Klein P, Pezzullo JC, Serje A. Premature ovarian failure in women with epilepsy. Epilepsia 2001;42:1584-1590.
  4. Klein P, van Passell-Clark L, Pezzullo JC. Onset of Epilepsy at the time of menarche. Neurology 2003;60:495-7.
  5. Herzog AG, Coleman AE, Jacobs AR, Klein P, Friedman MN, Drislane FW, Schomer DL. Relationship of sexual function to the laterality and reproductive hormone levels in women with temporolimbic epilepsy. Epilepsy Behav 2003;4:407-13.
  6. Herzog AG, Coleman AE, Jacobs AR, Klein P, Friedman MN, Drislane FW, Ransil BJ, Schomer DL. Interictal EEG discharges, reproductive hormones and menstrual disorders in epilepsy. Ann Neurol 2003;54:625-37.
  7. Sahoo S, Klein P. Maternal Complex partial seizure associated with fetal distress. Arch Neurol 2005;62:1304-05.
  8. Klein P, Sahoo S. Effect of ACTH-induced hypercortisolemia on EEG in patients with stress-related epilepsy. Epilepsy Behav 2005;6:187-190.
  9. Klein P, van Passell-Clark L. Effect of stress related to the 9/11/2001 terror attack on seizures in patients with epilepsy.Neurology 2005;64:1815-16.
  10. Thorneycroft I, Klein P, Simon J. Impact of antiepileptic drug therapy on steroidal contraceptive efficacy. Epilepsy Behav 2006; 9:31-39.
  11. Klein P, Cantero J, Tirol F, Pezzullo JC. Effect of hormonal contraception on seizures in women with epilepsy. Epi Res(submitted).
  12. Klein P, Janousek J, Barber A, Weissberger R. Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav 2010; 19:575-9.
  13. Klein P, Herr D, Pearl PL, et.al. Results of Phase II Safety and Feasibility Study of Treatment With Levetiracetam for Prevention of Posttraumatic Epilepsy. Arch Neurol 2012; Jul 9:1-6. doi: 10.1001/archneurol.2012.445.
  14. Klein P, Herr D, Pearl PL, et.al. Results of Phase II Pharmacokinetic Study of Levetiracetam for Prevention of Posttraumatic Epilepsy. Epi Behav 2012; 2012 Jul 7.
  15. Pearl PL, Herr D, Klein P. Results of phase II levetiracetam trial following acute head injury in children at risk for post-traumatic epilepsy. Epilepsia 2013; 54: (9):e135-7. doi: 10.1111/epi.12326. Epub 2013 Jul 22.
  16. Klein P, Mathews GC. Antiepileptic drugs and neurocognitive development, Editorial. Neurology 2014; 82:194-195.
  17. Klein P, Tyrlikova I, Mathews GC. Dietary treatment of refractory epilepsy in Adults. Neurology 2014; 83:in press.
  18. Tomson T, Klein P Fine-tuning risk assessment with antiepileptic drug use in pregnancy. Editorial. Neurology 2014; 83: 2015, in press.
  19. Klein P, Tyrlikova I, Mathews G. Dietary treatment in adults with refractory epilepsy, a review. Neurology 2014;83:1978–1985
  20. Klein P, Mathews G. Antiepileptic drugs and neurocognitive development, an editorial. Neurology  2014;82:194–195
  21. Lee D, Kalu U, Halford J, Biton V, Cloyd J, Klein P, Bekersky I, Peng G, Dheerendra S, Tolbert D. Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials. Epilepsia 2015, 56(6):906–914
  22. Klein P, Schiemann J, Sperling M, et.al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015, 56(12):1890–1898
  23. Ben-Menachem E, Mameniskiene R, Quarato P, Klein P, Gamage J, Schiemann J, Johnson M, Whitesides J, McDonough B, Eckhardt K. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology 2016;87:314–323
  24. Klein P, Tyrlikova I. Prevention of epilepsy: Should we be avoiding clinical trials?. Epilepsy & Behavior 2017; 72:188-194
  25. Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clinical Pharmacology: Advances and Applications 2018; 10:1-22
  26. Sperling M, Klein P, Tsai J. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures. Epilepsia 2017, 58(4):558-564
  27. Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy & Behavior 2018; 80: 129-134
  28. Klein P, Dingledine R, Aronica E, et al. Commonalities in epileptogenic processes from different acute brain insults: Do they translate? Epilepsia 2017;00:1-30

Dr. Amanda Pong

Bibliography

Original Articles

  1. Chalmers-Redman RM, Fraser AD, Carlile GW, Pong A, Tatton WG. “Glucose Protection from MPP+-induced Apoptosis Depends on Mitochondrial Membrane Potential.” Biochemical and Biophysical Research Communications. 257(2):440-7, 13 Apr 1999.
  2. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. “Reduced Apoptosis after Nerve Growth Factor and Serum Withdrawal: Conversion of Tetrameric Glyceraldehyde-3-phosphate Dehydrogenase to a Dimer.” Molecular Pharmacology. 57(1):2-12, Jan 2000.
  3. Tatton WG, Chalmers-Redman RME, Ju WJH, Mammen M, Carlile GW, Pong AW, Tatton NA. “Propargylamines induce apoptotic new protein synthesis in serum and nerve growth factor (NGF)-withdrawn, NGF-derived PC12 cells.” Journal of Pharmacologic and Experimental Therapy. 301(2):753-64, May 2002.
  4. Pong AW, Eksioglu YZ, Takeoka M. ARX mutations in females: an under-recognized cause of epilepsy and developmental delay. Biology of Seizure Susceptibility in Developing Brain. Progress in Epileptic Disorders, 6:65-74, 2008.
  5. Depositaro-Cabacar DF, Peters J, Pong AW, Roth J, Rotenberg A, Riviello JJ, Takeoka M. High-Dose Intravenous Levetiracetam for Acute Seizure Exacerbation in Children with Intractable Epilepsy. Epilepsia, 2010;51:1319-22.
  6. Pong AW. Vigabatrin (Sabril) for Epilepsy. The Medical Letter on Drugs and Therapeutics, 1332, 2010 Feb 22.
  7. Pal DK, Pong AW, Chung WK. Genetic Evaluation and Genetic Counseling for Epilepsy. Nature Reviews Neurology, 2010;6:445-53.
  8. Obeid M, Pong AW. Efficacy and tolerability of high oral doses of Levetiracetam in children with epilepsy. Epilepsy Research, 2010;91:101-5.
  9. Pong AW, Pal DK, Chung WK. Developments in Molecular Genetic Diagnostics: an Update for the Epilepsy Specialist. Pediatric Neurology, 2011;44:317-27.
  10. Eksioglu Y, Pong AW, Takeoka M. A Novel Mutation in the Aristaless Domain of the ARX Gene Leads to Ohtahara Syndrome, Global Developmental Delay and Ambiguous Genitalia in Males and Neuropsychiatric Disorders in Females. Epilepsia, 2011 May;52(5):984-92.
  11. Pong AW, Geary B, Engelstad K, Natarajan A, Yang H, De Vivo DC. Glucose Transporter Type I Deficiency Syndrome: epilepsy phenotypes and outcomes. Epilepsia, 2012 Sep:53(9):1503-10.
  12. Pong AW, De Vivo DC. Glucose Transporter Type I Deficiency Syndrome. Inherited Metabolic Epilepsies, Demos Medical, 2013; 179-88.
  13. Pong AW, Ross J, Tyrlikova I, Giermek AJ, Kohli MP, Khan YA, Salgado RD, Klein P. Epilepsy: Expert Opinion on Emerging Drugs in Phase 2/3 Clinical Trials. Expert Opinion on Emerging Drugs, 2022, 27:1, 75-90, DOI: 10.1080/14728214.2022.2059464.
  14. Pong AW, Tyrlikova I, Giermek AJ, Klein P. Impact of regulatory safety warnings and restrictions on drug treatment of epilepsy. Expert Opin Drug Saf. 2023 Feb;22(2):111-114. doi: 10.1080/14740338.2023.2188189. Epub 2023 Mar 9. PMID: 36881668.
  15. Pong AW, Xu KJ, Klein P. Recent advances in pharmacotherapy for epilepsy. Curr Opin Neurol. 2023 Apr 1;36(2):77-85. doi: 10.1097/WCO.0000000000001144. Epub 2023 Feb 10. PMID: 36762638.


Abstracts

  1. 2nd International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. (Munich, Germany, 11-14 Sept 1997): Tatton, William G. “Apoptosis in Neurodegeneration: An Opportunity for Neuroprotection.”
  2. 2nd International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics (Munich, Germany, 11-14 Sept 1997): Tatton, William G. “(-)-Desmethyl Deprenyl Reduces Ganglion Cell Apoptosis Caused by Optic Nerve Crush.”
  3. Association for Research in Vision and Opthalmology Symposium (1998): Mittag, T., G. Pohorenec, H.M. Yuan, A. Bayer, J. Danias, S. Cha, B. Ambati, R. Chalmers-Redman, A. Pong, S.M. Podos, W.G. Tatton. “Retinal Damage in a Rat Glaucoma Model.”
  4. Society for Neuroscience Abstracts (1998): Shashidaran, P., R. Redman-Chalmers, T. Yuen, A. Fraser, V. Rodic, A. Pong, W.G. Tatton and S.C. Sealfon. “Green Fluorescent Protein Reveals Nuclear Translocation of GAPDH during Apoptosis in Living Cells.”
  5. 13th Annual International Congress on Eye Research (Paris, 26-31 July 1998) Tatton, William G., R. Chalmers-Redman, A. Pong, A. Fraser, N. Tatton, H. Rideout, G. Carlile, and K. Borden. “Maintenance of Mitochondrial Impermeability in Early Apoptosis: An Opportunity for Retinal Neuroprotection.”
  6. 10th Annual Meeting of the Infantile Seizure Society (Tokyo, Japan, April 2007): Pong AW, Eksioglu YZ, Takeoka M. “ARX mutations in females: an under-recognized cause of epilepsy and developmental delay.”
  7. 10th Annual Meeting of the Infantile Seizure Society (Tokyo, Japan, April 2007): Eksioglu YZ, Pong AW, Takeoka M. “Mental retardation and neuropsychiatric symptoms in a female with compression in the first polyalanine tract of the ARX gene.”
  8. 10th Annual Meeting of the Infantile Seizure Society (Tokyo, Japan, April 2007): Eksioglu YZ, Pong AW, Takeoka M. “West syndrome in a girl with compression in the second polyalanine tract of the ARX gene.”
  9. 61st Annual Meeting of the American Epilepsy Society (Philadelphia, USA, November 2007): Pong AW, Warfield S, Cabacar-Depositario D, Peters J, Hussein AM, Duffy FH, Takeoka M. “Diffusion Tensor Tractography in Epilepsy Surgery Planning for Focal Cortical Dysplasia.”
  10. 61st Annual Meeting of the American Epilepsy Society (Philadelphia, USA, November 2007): Depositario-Cabacar D, Peters J, Pong AW, Roth J, Rotenberg A, Riviello J, Takeoka M. “High-dose Intravenous Levetiracetam for Acute Seizure Exacerbation in Children with Intractable Epilepsy.”
  11. 11th Annual Meeting of the Infantile Seizure Society (Shiga, Japan, April 2008): Pong AW, Takeoka M. “High Dose Levetiracetam and Refractory Epilepsy in Patients with SCN1A Mutations.”
  12. 62nd Annual Meeting of the American Epilepsy Society (Seattle, USA, December 2008): Pong AW, O’Mahony E, Sarco D, Wang SG, Pinto A, Poduri A, Takeoka M. “Interictal Epileptiform Activity in Children with Mesial Temporal Sclerosis.”
  13. 62nd Annual Meeting of the American Epilepsy Society (Seattle, USA, December 2008): Wang SG, O’Mahony E, Poduri A, Pong AW, Pinto A, Sarco D, Takeoka M. “Mesial Temporal Sclerosis in Children; A Longitudinal Study of 4 Cases.”
  14. 64nd Annual Meeting of the American Epilepsy Society (San Antonio, USA, December 2010): Obeid M, Pong AW. “Efficacy and tolerability of high oral doses of Levetiracetam in children with epilepsy.”
  15. 12th International Congress of Human Genetics and the American Society of Human Genetics (Montreal, CA, October 2011): Pong AW, Geary B, Engelstad K, Natarajan A, Yang H, De Vivo DC. “Glucose Transporter Type I Deficiency Syndrome epilepsy phenotypes and therapy: implications for genetic testing, counseling, and treatment from a large cohort.
Scroll to Top